What is RetiSpec?
RetiSpec Inc. is a Toronto-based medical imaging company pioneering a non-invasive, machine learning-driven tool for the early detection of Alzheimer's disease biomarkers within the eye. Their approach offers a more accessible and scalable screening method compared to existing practices, aiming to facilitate widespread early diagnosis of Alzheimer's pathology. The company is actively supported by networks such as the Ontario Brain Institute (OBI) and NEXT Canada, positioning it at the forefront of aging and brain health innovation.
How much funding has RetiSpec raised?
RetiSpec has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Topcon Healthcare, iGan Partners, and Eli Lilly
Key Investors in RetiSpec
Topcon Healthcare
Topcon Healthcare, a division of Topcon Corporation, specializes in advanced optical and digital solutions for the medical industry, focusing on enhancing disease detection and patient care through innovative technologies.
iGan Partners
iGan Partners is a prominent venture capital firm dedicated to investing in and scaling innovative healthcare solutions across North America, providing strategic support and access to industry networks.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical leader focused on the discovery, development, and commercialization of medicines, with a significant interest in neuroscience and neurodegenerative diseases.
What's next for RetiSpec?
The substantial enterprise-level funding secured by RetiSpec signals a critical phase of scaling and market penetration. This capital injection is expected to accelerate the development and commercialization of their diagnostic technology, potentially expanding its reach to a global audience. Strategic partnerships and further research into Alzheimer's biomarkers will likely be key priorities as the company aims to solidify its position as a leader in early disease detection.
See full RetiSpec company page
